Angiotensin II type 1 receptor blockade attenuates renal fibrogenesis in an immune-mediated nephritic kidney through counter-activation of angiotensin II type 2 receptor

Biochemical and Biophysical Research Communications

Volumn 314, Issue 2, 2004, Pages 403-408

  Okada, Hirokazu ^a   Watanabe, Yusuke ^a   Inoue, Tsutomu ^a   Kobayashi, Tatsuya ^a   Kikuta, Tomohiro ^a   Kanno, Yoshihiko ^a   Ban, Shinichi ^a   Suzuki, Hiromichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II type 1A receptor; Angiotensin II type 2 receptor; Antagonist; Anti glomerular basement membrane nephritis; Plasminogen activator inhibitor 1; Renal fibrogenesis; Transforming growth factor 1; Type I collagen

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; COLLAGEN TYPE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; FIBROGENESIS; GENE EXPRESSION; GLOMERULUS BASEMENT MEMBRANE; KIDNEY FIBROSIS; MALE; MOUSE; NEPHRITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR BLOCKING;

EID: 0347004648     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.12.105     Document Type: Article

References (31)

1. Taal M.W., Brenner B.M. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 57:2000;1803-1817.
2. Matsusaka T., Hymes J., Ichikawa I. Angiotensin in progressive renal diseases: theory and practice. J. Am. Soc. Nephrol. 7:1996;2025-2043.
3. Ruiz-Ortega M., Lorenzo O., Suzuki Y., Ruperez M., Egido J. Proinflammatory actions of angiotensins. Curr. Opin. Nephrol. Hypertens. 10:2001;321-329.
4. Ruggenenti P., Perna A., Gherardi G., Gaspari F., Benini R., Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial: Gruppo Italiano di Studi Epidemiologici in Nefrologia: Ramipril efficacy in nephropathy. Lancet. 352:1998;1252-1256.
5. Maschio G., Alberti D., Janin G., Locatelli F., Mann J.F., Motolese M., Ponticelli C., Ritz E., Zuchelli P. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N. Engl. J. Med. 334:1996;1863-1875.
6. Inagami T. Molecular biology and signaling of angiotensin receptors: an overview. J. Am. Soc. Nephrol. 10:1999;S2-S7.
7. Hisada Y., Sugaya T., Yamanouchi M., Uchida H., Fujimura H., Sakurai H., Fukamizu A., Murakami K. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J. Clin. Invest. 103:1999;627-635.
8. Nagamatsu T., Hayashi K., Oka T., Suzuki Y. Angiotensin II type I receptor antagonist suppresses proteinuria and glomerular lesions in experimental nephritis. Eur. J. Pharmacol. 374:1999;93-101.
9. Suzuki Y., Lopez-Franco O., Gomez-garre D., Tejera N., Gomez-Guerrero C., Sugaya T., Bernal R., Blanco J., Ortega L., Egido J. Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice. Am. J. Pathol. 159:2001;1895-1904.
10. Lafayette R., Mayer G., Park S.K., Meyer T.W. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 90:1992;766-771.
11. Ishidoya S., Morrissey J., McCracken R., Reyes A., Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int. 47:1995;1285-1294.
12. Satoh M., Kashihara N., Yamasaki Y., Maruyama K., Okamoto K., Maeshima Y., Sugiyama H., Sugaya T., Murakami K., Makino H. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J. Am. Soc. Nephrol. 12:2001;317-325.
13. Remuzzi A., Perico N., Amuchastegui C.S., Malanchini B., Mazerska M., Battaglia C., Bertani T., Remuzzi G. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J. Am. Soc. Nephrol. 4:1993;40-49.
14. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Rmuzzi G., Snapinn S.M., Zhang Z., Shahinfar S. RENAAL study investigators, effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345:2001;861-869.
15. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease: a randomised controlled trial. Lancet. 361:2003;117-124.
16. Matsubara H. Pathophysiological role of antiogensin II type 2 receptor in cardiovascular and renal diseases. Circ. Res. 83:1998;1182-1191.
17. Stoll M., Unger T. Angiotensin and its AT2 receptor: new insights into an old system. Reg. Pept. 99:2001;175-182.
18. Morrissey J.J., Klahr S. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am. J. Physiol. 276:1999;F39-F45.
19. Ma J., Nishimura H., Fogo A., Kon V., Inagami T., Ichikawa I. Accelerated fibrosis and collagen deposition develop in the real interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int. 53:1998;937-944.
20. Cao Z., Bonnet F., Candido R., Nesteroff S.P., Burns W.C., Kawachi H., Shimizu F., Carey R.M., de Gasparo M., Cooper M.E. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J. Am. Soc. Nephrol. 13:2002;1773-1787.
21. Cervenka L., Heller J., Jelinek F. Lack of a beneficial effect of PD123319, an AT2-angiotensin receptor antagonist, on the course of ablation nephropathy in the rat. Kidney Blood Press. Res. 19:1996;241-244.
22. Okada H., Inoue T., Kanno Y., Kobayashi T., Watanabe Y., Kopp J.B., Carey R.M., Suzuki H. Interstitial fibroblast-like cells express renin-angiotensin system components in a fibrosing murine kidney. Am. J. Pathol. 160:2002;765-772.
23. Eddy A. Molecular basis of renal fibrosis. Pediatr. Nephrol. 15:2000;290-301.
24. Remuzzi G., Bertani T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 390:1998;1448-1456.
25. Horiuchi M., Akishima M., Dzau V.J. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 33:1999;613-621.
26. Wolf G., Ziyadeh F.N., Thaiss F., Tomaszewski J., Caron R.J., Wenzel U., Zahner G., Helmchen U., Stahl R.A.K. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. J. Clin. Invest. 100:1997;1047-1058.
27. Cao Z., Kelly D.J., Cox A., Casley D., Forbes J.M., Maartinello P., Dean R., Gilbert R.E., Cooper M.E. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int. 58:2000;2437-2451.
28. Hisada Y., Sugaya T., Tanaka S., Suzuki Y., Ra C., Kimura K., Fukamizu A. An essential role of angiotensin II receptor type 1a in recipient kidney, not in transplanted peripheral blood leukocytes, in progressive immune-mediated renal injury. Lab. Invest. 81:2001;1243-1251.
29. Anderson S., Rennke H.G., Brenner B.M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 77:1986;1993-2000.
30. Navar L.G., Harrison-Bernard L.M., Nishiyama A., Kobory H. Regulation of intrarenal angiotensin II in hypertension. Hypertension. 39:2002;316-322.
31. Arima S., Endo Y., Yaoita H., Omata K., Ogawa S., Tsunoda K., Abe M., Takeuchi K., Abe K., Ito S. Possible role of P450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J. Clin. Invest. 100:1997;2816-2823.